Please assess the completion status of the following clinical trial:

Trial Title: Argatroban Plus r-tPA for Posterior Circulation Infarction（AR-PCI）

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 18-80 years old;~2. Diagnosis of posterior circulation ischemic stroke;~3. Time from onset to treatment ≤6 hours;~4. NIHSS: 4-25;~5. Signed informed consent by patient self or legally authorized representatives.~Exclusion Criteria:~1. mRS≥2;~2. History of stroke within 3 months;~3. History of intracranial hemorrhage;~4. Suspected subarachnoid hemorrhage;~5. Intracranial tumour, vascular malformation or arterial aneurysm;~6. Major surgery within 1 month;~7. Systolic pressure ≥180 mmHg or diastolic pressure ≥110 mmHg;~8. Platelet count \< 105/mm3;~9. Heparin therapy or oral anticoagulation therapy within 48 hours;~10. Abnormal APTT;~11. Thrombin or Xa factor inhibitor;~12. Severe disease with a life expectancy of less than 3 months;~13. Blood glucose \< 50 mg/dL (2.7mmol/L);~14. Patients who have received any other investigational drug or device within 3 months;~15. Pregnancy;~16. Researchers consider patients inappropriate to participate in the registry.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Argatroban combined with rt-PA (Type: EXPERIMENTAL): None
- rt-PA (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).